Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 17/20 | 1.00 |
| ▸ | PDE4A | P27815 | 11/20 | 0.66 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 10/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.65 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17088233 | 1.00 | PDE10A (1.00) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL30123130 | 0.86 | PDE10A (0.76) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL4724444 | 0.86 | PDE10A (0.76) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL17088215 | 0.86 | PDE10A (0.75) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL24951316 | 0.82 | PDE10A (0.70) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL31133594 | 0.82 | PDE10A (0.70) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL3276042 | 0.81 | PDE10A (0.69) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL4154400 | 0.81 | PDE10A (0.68) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL5532970 | 0.81 | PDE10A (0.67) | PDE10APDE4APDE4BPDE3BPDE3A | |
| SCHEMBL3269654 | 0.80 | PDE10A (0.81) | PDE10APDE4APDE4BPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058894-A1 | RADIOLABELED PDE10A LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2016-03-03 | — | — | US | disclosed |
| US-9138494-B2 | Radiolabeled PDE10A ligands | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058894-A1 | RADIOLABELED PDE10A LIGANDS | PDE10A, PDE3A, PDE5A | PDE10A 1/4885PDE4A 9/4885PDE4B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.